89332-50-3

Basic information

• Product Name: Cilostazol-d11
• Synonyms: 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinon;Cilostazol-d11;OPC-13013-d11;Pletal-d11;CILOSTAZOL METABOLITE;OPC013015;2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-;2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
• CAS NO: 89332-50-3
• Molecular Formula: C20H16D11N5O2
• Molecular Weight: 380.528459558
• Product Categories: Intermediates & Fine Chemicals;Isotope Labeled Compounds;Pharmaceuticals
• Mol File: 89332-50-3.mol
• Article Data: 18

Chemical Properties

• Melting Point: 159-160°C
• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly, Sonicated)
• CAS DataBase Reference: Cilostazol-d11(CAS DataBase Reference)
• NIST Chemistry Reference: Cilostazol-d11(89332-50-3)
• EPA Substance Registry System: Cilostazol-d11(89332-50-3)

Safety Data

• Hazardous Substances Data: 89332-50-3(Hazardous Substances Data)

Upstream product

• 54197-66-9 3,4-dihydro-6-hydroxy-2(1H)-quinolinone 
• 73963-42-5 1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole 
• 5470-65-5 3-bromo-4-nitrophenol 
• 104-94-9 4-methoxy-aniline 
• 877303-63-4 cilostazol oxalate 
• 877303-65-6 cilostazol bisulfate 
• 877303-64-5 cilostazol malate 

Downstream Products

• 93632-84-9 OPC-13326 
• 87153-03-5 3,4-Dihydro-6-<4-<1-(cis-2-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone 
• 98360-32-8 3,4-Dihydro-6-<4-<1-(trans-3-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone 
• 98360-32-8 3,4-Dihydro-6-<4-<1-(cis-3-hydroxycyclohexyl)-1H-tetrazol-5-yl>butoxy>-2(1H)-quinolinone 
• 87153-04-6 OPC 13213 
• 87153-06-8 OPC 13217 
• 1266615-52-4 CLZ-DDQ 
• 1266615-51-3 CLZ-I₂ 

Relevant articles and documents

METHODS FOR PREPARING CILOSTAZOL AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a method for preparing cilostazol and a pharmaceutical formulation comprising the same. A method for preparing crystalline A cilostazol and a cilostazol pharmaceutical preparation manufactured by using the same are provided. The cilostazol prepared according to the method of the present invention has high yield, has high purity, has a low impurity content, and has less side effects and excellent emission characteristics. A method for preparing cilostazol according to the present invention is characterized by having less environmental pollution compared to the conventional method using a single catalyst. (by machine translation)

Preparation method of cilostazol

The invention discloses a preparation method of cilostazol and belongs to the field of medicines. The preparation method comprises the following steps: firstly, reacting 4-methoxyaniline with 3-chloropropionyl chloride in the presence of a solvent or no solvent; after a TLC (thin layer chromatography) detecting reaction is finished, adding aluminum trichloride into a system, and carrying out temperature raising reaction for 1 to 16 hours to obtain 6-hydroxy-3,4-dihydroquinoline-2-keto; secondly, in the presence of alkali, carrying out heating reaction on the 6-hydroxy-3,4-dihydroquinoline-2-keto obtained in the first step and 5-(4-chlorobutyl)-1-cyclohexanyl tetrazole in normal propyl alcohol to obtain the cilostazol. The high-purity cilostazol can be obtained by adopting the method disclosed by the invention; the preparation method has the advantages of few steps of the whole synthetic route, high yield, low cost, less wastewater and suitability for industrial production.

Convergent Three-Component Tetrazole Synthesis

A microwave-accelerated, simple, and efficient method for the construction of the 1,5-tetrazole scaffold was developed. It comprises a multicomponent reaction of an amine, a carboxylic acid derivative, and an azide source. On the basis of the availability of the archetypical starting materials, this method provided very versatile synthetic access to 1,5-disubstituted tetrazoles. The usefulness of this method was demonstrated in the synthesis of biologically important fused tetrazole scaffolds and the marketed drug cilostazol.